Table 2.
Treatment characteristic of the included studies.
| Study | Clinical stages | Regimens | Dosage | No. of cycles | ECOG PS | Outcomes |
|---|---|---|---|---|---|---|
| Chen et al. (35) | T1-4, N0-1 | C-GEMOX GEMOX |
Cetuximab:500 mg/m2; gemcitabine: 800 mg/m2; oxaliplatin:85 mg/m2 | NA | 0/1 | OS; PFS; ORR |
| Fiteni et al. (38) | NA | GEMOX GC |
Gemcitabine: 1000 mg/m2; oxaliplatin: 100 mg/m2; carboplatin: according to an area-under-the-curve | 7 | 0/1/2/3 | OS; PFS; ORR |
| Kang et al. (28) | NA | GP SP |
Gemcitabine: 1000 mg/m2; cisplatin: 60 mg/m2; S-1: 40 mg/m2 | 6 | 0/1/2 | OS; PFS; ORR |
| Kim et al. (27) | IVa, IVb | XPRT XP |
Capecitabine: 1000 mg/m2; cisplatin: 30 mg/m2; radiotherapy: 25-60 Gy | XPRT: 6 XP: 4 |
0/1/2 | ORR |
| Park et al. (24) | NA | XP GP |
Gemcitabine: 1000 mg/m2; cisplatin: 25/60 mg/m2; capecitabine: 1000 mg/m2; | XP: 6 GP: 4 |
0/1/2 | OS; PFS; ORR |
| Lee et al. (13) | NA | GEMOX E-GEMOX |
Gemcitabine: 1000 mg/m2; oxaliplatin: 100 mg/m2; erlotinib: 100 mg/day | GEMOX: 6 E-GEMOX: 7 |
0/1/2 | OS; PFS; ORR |
| Lee et al. (25) | NA | GP XP |
Gemcitabine: 1000 mg/m2; cisplatin: 75/60 mg/m2; capecitabine: 1250 mg/m2; | GP: 4 XP: 3 |
NA | ORR |
| Lenoe et al. (15) | NA | Pa-GEMOX GEMOX |
Gemcitabine: 1000 mg/m2; oxaliplatin:100 mg/m2; panitumumab: 6 mg/kg | 12 | 0/1/2 | OS; PFS; ORR |
| Li et al. (36) | NA | GS GEM S-1 |
Gemcitabine: 1000 mg/m2; S-1: 80/100/120 mg/d | NA | NA | OS; PFS; ORR |
| Malka et al. (12) | NA | C-GEMOX GEMOX |
Cetuximab: 500 mg/m2; gemcitabine: 1000 mg/m2; oxaliplatin: 100 mg/m2 | 10 | 0/1 | OS; PFS; ORR |
| Moehler et al. (14) | NA | GSo GEM |
Gemcitabine: 1000 mg/m2; soragenib: 400 mg/day | 4 | 0/1/2 | OS; PFS |
| Morizane et al. (32) | II / III /IV /recurrent | GS S-1 |
Gemcitabine: 1000 mg/m2; S-1(combination): 60 mg/m2; S-1(monotherapy): 80 mg/m2 | GS: 10 S-1: 3 |
0/1 | OS; PFS |
| Novariono et al. (34) | NA | Folfox-4 GEM |
Oxaliplatin: 85 mg/m2; folinic acid: 200 mg/m2; 5-FU: 400/600 mg/m2; gemcitabine: 1250 mg/m2 | Folfox-4: 6 GEM: 3 |
0/1/2 | OS; PFS; ORR |
| Okusaka et al. (8) | II/IIIA-C/IV/recurrent | GP GEM |
Gemcitabine: 1000 mg/m2; cisplatin: 25 mg/m2 | GP: 4 GEM: 3 |
0/1 | OS; PFS; ORR |
| Phelip et al. (39) | NA | FUPR GEMOX |
5-FU: 300 mg/m2; cisplatin: 80 mg/m2; radiotherapy: 50 Gy; gemcitabine: 1000 mg/m2; oxaliplatin: 100 mg/m2 | NA | 0/1/2 | OS; PFS |
| Woo et al. (26) | NA | XP GP |
Gemcitabine: 1000 mg/m2; cisplatin: 25/30 mg/m2; capecitabine: 1000 mg/m2; | 3 | NA | OS; ORR |
| Santoro et al. (33) | NA | V GV GEM |
Vandetanib: 300 mg/m2; vandetanib(combination): 100 mg/m2; gemcitabine: 1000 mg/m2 | 6 | 0/1/2 | PFS |
| Sasaki et al. (30) | NA | GS GEM |
Gemcitabine: 1000 mg/m2; S-1: 40 mg/m2 | NA | 0/1/2 | OS; ORR |
| Schinzari et al. (9) | NA | Folfox-4 FUFA |
NA | NA | NA | OS; PFS |
| Sharma et al. (40) | NA | BSC FUFA GEMOX |
5-FU: 425 mg/m2; folinic acid: 20 mg/m2; gemcitabine: 900 mg/m2; oxaliplatin: 80 mg/m2 | 6 | 0/1/2 | OS; PFS; ORR |
| Takahara et al. (31) | NA | GS GP |
Gemcitabine: 1000 mg/m2; S-1: 80 mg/m2; cisplatin: 25 mg/m2 | GS: 4 GP: 5 |
0/1/2 | OS; PFS; ORR |
| Valle et al. (7) | NA | GEM GP |
Gemcitabine: 1000 mg/m2; cisplatin: 25 mg/m2; | 6 | 0/1/2 | OS; PFS |
| Valle et al. (37) | NA | GPCe GP |
Gemcitabine: 1000 mg/m2; cisplatin: 25 mg/m2; cediranib: 20 mg/day | 8 | 0/1 | OS; PFS |
| Vogel et al. (41) | M0, M1, MX | GPPa GP |
Gemcitabine: 1000 mg/m2; cisplatin: 25 mg/m2; panitumumab: 9 mg/kg | GPPa: 8 GP: 6 |
0/1/2 | OS; PFS |
| Yonemoto et al. (29) | NA | S-1 GEM FAM BSC |
NA | NA | 0/1/2/3/4 | OS |
ECOG PS, Eastern Cooperative Oncology Group Performance Status; NA, not available; GEM, gemcitabine; OX, oxaliplatin; C, cetuximab; E, erlotinib; Pa, panitummumab; GC, gemcitabine+carboplatin; GP, gemcitabine+cisplatin; SP, S-1 +cisplatin; XP, capecitabine +cisplatin; RT, radiotherapy; GSo, gemcitabine+sorafenib; GS, gemcitabine+S-1; Folfox-4, 5-FU+folinic acid+oxaliplatin; FUPR, 5-FU+cisplatin+radiotherapy; FUFA, 5-FU+folinic acid; Ce, cediranib; V, vandetanib; GV, vandetanib+gemcitabine; FAM, 5-FU+doxorubicin+mitomycin C; BSC, best support care; OS, overall survival; PFS, progression free survival; ORR, objective response rate.